TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04067219

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DXA (dual-energy x-ray absorptiometric) measurement
Description: DXA, evaluation of muscular function and muscle strength; neurocognitive tests; non invasive analysis of mechanical skin properties; food frequency questionnaire; laboratory assessment (25 hydroxy vitamin D, calcium/phosphate metabolism, bone remodelling markers, T cell activation).
Study: NCT02178241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study: NCT02334436

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin, Type A
Description: Botulinum toxin, Type A

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sterile, unpreserved saline
Description: Placebo Comparator Arm
Study: NCT04962750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low level laser therapy
Description: Low level laser therapy from suitable machine

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: The device wasn't working
Study: NCT02658240

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine 300 mg and 0.5 mg epinephrine diluted to 60 mL
Study: NCT03729934

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone Ester
Description: This arm receives 25 g ketone ester.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone Salt
Description: This arm receives 25 g ketone salt.
Study: NCT03090997

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin C (500 mg / day) and resveratrol (500 mg / day)
Description: Adminstration of resveratrol (500 mg / day/orally) + vitamin C 500 mg/day/orally)
Study: NCT01641133

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Synflorix (3-Dose)
Description: 3 doses administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synflorix (2-Dose)
Description: 2 doses administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synflorix (Single Dose)
Description: 1 dose administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar 13 (Single Dose)
Description: 1 dose administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar 13 (2-Dose)
Description: 2 doses administered intramuscularly
Study: NCT00974961

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine, levobupivacaine
Description: intrathecal injection 15\~20mg(for Levobupivacaine) or 10\~15mg(for Bupivacaine) once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine, levobupivacaine
Description: intrathecal injection 15\~20mg(for Levobupivacaine) or 10\~15mg(for Bupivacaine) once
Study: NCT04309253

Intervention type: DRUG
Group type: OTHER
Intervention: PMPBB3
Description: F-18 PMPBB3 PET Imaging

Intervention type: DRUG
Group type: OTHER
Intervention: PMPBB3
Description: F-18 PMPBB3 PET Imaging
Study: NCT02658240

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine 300 mg and 0.5 mg epinephrine diluted to 60 mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: 0.5 mg epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: 0.5 mg epinephrine
Study: NCT00993395

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: peer mentor-based disease management
Description: peer mentor-based disease management focused on three domains: medical care, recovery, and social stabilization
Study: NCT01105221

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Participants, allocated to this group, will have twelve times of acupuncture treatment in four weeks. Seventeen acupuncture points, which are both BL2, GB14, TE23, Ex1, ST1, GB20, LI4, LI11 and single GV23, will be selected and disposable 0.20\*30mm acupuncture needles(Dongbang Co., Korea) will be inserted on these points. Strong 'deqi' sensation will be induced by twisting acupuncture needles and retained for 20 minutes before removed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Refresh Plus
Description: Participants, allocated to this group, will be offered preservative-free and single-use Refresh plus (Sodium carboxymethylcellulose). They should use artificial tear in both eyes at least once a day for four weeks.
Study: NCT04059406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sapablursen
Description: sapablursen administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sapablursen
Description: sapablursen administered subcutaneously
Study: NCT04309253

Intervention type: DRUG
Group type: OTHER
Intervention: AV45
Description: F-18 AV45 PET Imaging

Intervention type: DRUG
Group type: OTHER
Intervention: AV45
Description: F-18 AV45 PET Imaging
Study: NCT02021370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY85-3934
Description: 25mg Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY85-3934
Description: 25mg Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY85-3934
Description: 25mg Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY85-3934
Description: 25mg Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY85-3934
Description: 25mg Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablet
Study: NCT03960047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Training
Description: This group gets trained to cross streets using virtual reality

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Streetside Training
Description: This group is trained to cross streets based on streetside experiences
Study: NCT02717650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A-STEP
Description: Study A) Study A) Development of new exercise test protocol and Observational Feasibility/Safety Study (no comparator).~Feasibility/safety of a newly designed, incremental, maximal, standardised step test in adults with Cystic Fibrosis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A-STEP (New Protocol)
Description: Study B) Validation Study (random allocation of test order). Validity of an incremental, maximal, standardised incremental step test with breath-by-breath gas analysis using portable metabolic measurement equipment against CPET.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: CPET cycle ergometer (Gold Standard)
Description: Study B) Validation study (random allocation of test order) Gold standard CPET. An incremental, maximal standardised cycle ergometer exercise test (performed as per published protocol) using portable metabolic measurement equipment.
Study: NCT01402869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% prilocaine plain
Description: 5mg/kg via infiltration into multiple sites of the buccal mucosa of mouth 1 time prior to start of restorative dental treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% Lidocaine with 1:100,000 epinephrine
Description: 2.5mg/kg via infiltration into multiple sites of buccal mucosa of mouth 1 time prior to restorative dental treatment
Study: NCT00788814

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pathways
Description: Strength-based curriculum addressing depression in women with with physical disabilities
Study: NCT04326790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Low-dose colchicine treatment, 0.5 mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Standard treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: Standard treatment
Study: NCT02991339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 10 mg iv for 2 days; then 5 mg iv for 1 day
Study: NCT03649802

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low dose vitamin D3
Description: Low dose arm-800 IU given daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High dose vitamin D3
Description: High dose arm-5000 IU given daily
Study: NCT03070990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin
Description: All subjects assigned will receive a single 30 minute intravenous infusion of enfortumab vedotin (ASG-22CE) once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin
Description: All subjects assigned will receive a single 30 minute intravenous infusion of enfortumab vedotin (ASG-22CE) once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is 28 days.
Study: NCT02962921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin LISPRO intravenous loading
Description: intravenous infusion of insulin Lispro.
Study: NCT02481258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataciguat (HMR1766)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Matching Placebo
Study: NCT01402960

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Definition Transcranial Direct Current Stimulation (HD-tDCS)
Description: Subject will receive active anodal/cathodal and sham HD-tDCS in a randomized, counterbalanced order. Each stimulation session will be separated by at least one week to avoid carryover effects. For both active and sham HD-tDCS the electrodes will be placed over the primary motor cortex, at an intensity of 2mA.~* For active anodal stimulation, the anode will be over the primary motor cortex, and the cathodal electrodes (4) will surround the anode in a 3 inch square, duration will be 20 minutes.~* For active cathodal stimulation, the cathode will be over the primary motor cortex, and the anodal electrodes (4) will surround the cathode in a 3 inch square, duration will be 20 minutes.~* For sham stimulation, the same procedure will be used, however, current will only be active for 30 seconds (current ramping up, then ramping down)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Definition Transcranial Direct Current Stimulation (HD-tDCS)
Description: Subject will receive active anodal/cathodal and sham HD-tDCS in a randomized, counterbalanced order. Each stimulation session will be separated by at least one week to avoid carryover effects. For both active and sham HD-tDCS the electrodes will be placed over the primary motor cortex, at an intensity of 2mA.~* For active anodal stimulation, the anode will be over the primary motor cortex, and the cathodal electrodes (4) will surround the anode in a 3 inch square, duration will be 20 minutes.~* For active cathodal stimulation, the cathode will be over the primary motor cortex, and the anodal electrodes (4) will surround the cathode in a 3 inch square, duration will be 20 minutes.~* For sham stimulation, the same procedure will be used, however, current will only be active for 30 seconds (current ramping up, then ramping down)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: High Definition Transcranial Direct Current Stimulation (HD-tDCS)
Description: Subject will receive active anodal/cathodal and sham HD-tDCS in a randomized, counterbalanced order. Each stimulation session will be separated by at least one week to avoid carryover effects. For both active and sham HD-tDCS the electrodes will be placed over the primary motor cortex, at an intensity of 2mA.~* For active anodal stimulation, the anode will be over the primary motor cortex, and the cathodal electrodes (4) will surround the anode in a 3 inch square, duration will be 20 minutes.~* For active cathodal stimulation, the cathode will be over the primary motor cortex, and the anodal electrodes (4) will surround the cathode in a 3 inch square, duration will be 20 minutes.~* For sham stimulation, the same procedure will be used, however, current will only be active for 30 seconds (current ramping up, then ramping down)
Study: NCT02021370

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet
Study: NCT04247152

Intervention type: OTHER
Group type: OTHER
Intervention: Intraoperative Aberrometry vs preoperative biometry
Description: Hypothesis: Intraoperative aberrometry measures lower levels of astigmatism more accurately than preoperative biometry in patients undergoing cataract surgery.
Study: NCT04053465

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat acclimation
Description: 14 days of aerobic exercise in a hot environment
Study: NCT03132285

Intervention type: DEVICE
Group type: OTHER
Intervention: PrePex
Description: Prepex is a non surgical male circumcision device
Study: NCT01027429

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: procaine penicillin and gentamicin
Description: procaine penicillin 50,000 units/kg by intramuscular injection once daily for 7 days; gentamicin, 5 mg/kg once daily by intramuscular injection for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin and gentamicin
Description: oral amoxicillin 80-90 mg/kg divided in two doses for 7 days intramuscular gentamicin, 5 mg/kg once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: procaine penicillin, gentamicin, amoxicillin
Description: procaine penicillin, 50,000 IU/kg once daily intramuscular injection plus gentamicin 5 mg/kg once daily intramuscular injection for 2 days, followed by 5 days of oral amoxicillin, 80-90 mg/kg divided in two doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: procaine penicillin, gentamicin, amoxicillin
Description: procaine penicillin, 50,000 IU/kg once daily intramuscular injection plus gentamicin 5 mg/kg once daily intramuscular injection for 2 days, followed by 5 days of oral amoxicillin, 80-90 mg/kg divided in two doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: procaine penicillin, gentamicin, amoxicillin
Description: procaine penicillin, 50,000 IU/kg once daily intramuscular injection plus gentamicin 5 mg/kg once daily intramuscular injection for 2 days, followed by 5 days of oral amoxicillin, 80-90 mg/kg divided in two doses.
Study: NCT01070342

Intervention type: DEVICE
Intervention: Spacelabs 90217
Description: Comparison of the two ways to measure blood pressure: using the ambulatory blood pressure device (Spacelabs 90217) versus the standard method of measuring blood pressure is done by using a stethoscope and a blood pressure cuff.
Study: NCT00611390

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: mixture of aromatic essential oils.
Description: 3% of mixture containing aromatic essential oils of Eucalyptus citriodora, Eucalyptus globulus, Mentha piperita, Origanum syriacum, and Rosmarinus Officinalis, spraying to the larynx.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.1% of Lemon VIP (Florasynth,Israel), spraying to the larynx.
Study: NCT02636647

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fecal transplant
Study: NCT03390725

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A Healthy School Start Plus intervention
Description: Intervention for prevention of childhood overweight and obesity in disadvantaged areas through parental support in the school setting

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A Healthy School Start Plus intervention
Description: Intervention for prevention of childhood overweight and obesity in disadvantaged areas through parental support in the school setting
Study: NCT04902209

Intervention type: PROCEDURE
Intervention: postural stability measurements
Description: Static balance assessment on bi-module stabilometric platform CQStab2P. It registers the movement of centre of foot pressure (COP).~Harris hip score- disability assesment

Intervention type: PROCEDURE
Intervention: postural stability measurements
Description: Static balance assessment on bi-module stabilometric platform CQStab2P. It registers the movement of centre of foot pressure (COP).~Harris hip score- disability assesment
Study: NCT00947219

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HairMax LaserComb
Description: Device application 3 times week (non-consecutive days), for 26 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HairMax LaserComb
Description: Device application 3 times week (non-consecutive days), for 26 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control device
Description: Device is used 3 times a week on non-consecutive days
Study: NCT04063917

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZENS
Description: ZENS transcutaneous nerve stimulator (ZENS Device), a wearable and non-invasive device which stimulates nerves in the neck to reduce airway obstruction and maintain muscular tension while sleeping to reduce snoring severity.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZENS
Description: ZENS transcutaneous nerve stimulator (ZENS Device), a wearable and non-invasive device which stimulates nerves in the neck to reduce airway obstruction and maintain muscular tension while sleeping to reduce snoring severity.
Study: NCT03905915

Intervention type: DEVICE
Group type: OTHER
Intervention: Virtual reality (VR) session with AQUA module
Description: A device with virtual reality is given to the patients with a film of 15 minutes
Study: NCT03490929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON]
Description: injection of Lumason (ultrasound contrast agent)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: contrast-enhanced ultrasound
Description: ultrasound of the abdomen after injection of ultrasound contrast agent (Lumason)
Study: NCT03960684

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Levita Magnetic Surgical System
Description: Levita Magnetic Surgical System
Study: NCT04053465

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise in a cool environment
Description: 14 days of aerobic exercise in a cool environment
Study: NCT04059406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sapablursen
Description: sapablursen administered subcutaneously
Study: NCT03761056

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered according to package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered according to package insert
Study: NCT06716866

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: temporally-interfering electric field stimulation
Description: Temporally-interfering electric field stimulation is a candidate non-invasive means to stimulate and modulate the nervous system. We do not know of any other trials of this method in epilepsy patients.
Study: NCT00402415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib malate
Description: C1: 50 mg po days 1-15, 2 weeks off C2: 50 mg po x 4 weeks, 2 weeks off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Dose escalation until MTD as follows:~C1: not given C2: 4 mg weekly, 8 mg weekly, 12 mg weekly, 20 mg weekly
Study: NCT00713323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex®
Description: containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
Study: NCT00631995

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Tetanus Protein Conjugate
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Tetanus Protein Conjugate
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Tetanus Protein Conjugate
Description: 0.5 mL, Intramuscular
Study: NCT01894464

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teacher led intervention
Study: NCT00631995

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Tetanus Protein Conjugate
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Tetanus Protein Conjugate
Description: 0.5 mL, Intramuscular
Study: NCT04167254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sit Down and Play
Description: Brief health care-based program that aims to promote key parenting behaviors that promote early childhood development
Study: NCT05227976

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient education (Theory)
Description: Theory/Lectures (1h/week)~Interventions given once weekly for 10 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient education (Theory)
Description: Theory/Lectures (1h/week)~Interventions given once weekly for 10 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient education (Theory)
Description: Theory/Lectures (1h/week)~Interventions given once weekly for 10 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical training
Description: Physical training group (1 hour/week)~Interventions given once weekly for 10 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness and medical yoga in group
Description: Mindfulness/medical yoga in group (1hour/week)~Interventions given once weekly for 10 weeks.
Study: NCT00631995

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal polysaccharide group C conjugated
Description: 0.5 mL, Intramuscular
Study: NCT04195087

Intervention type: DEVICE
Intervention: Masimo Radical-7® Pulse CO-Oximeter®
Description: The perfusion index and Pleth variability index will be recorded from the device monitor.
Study: NCT03898284

Intervention type: DIAGNOSTIC_TEST
Intervention: Impulse Oscillometry
Description: Impulse Oscillometry will be performed in addition to usual care